Table 2.
Cytotoxicity assays. Cells (3–8 × 103·mL−1) were treated for 72 h with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test. IC50 values were calculated by a four parameter logistic model (p < 0.05). S.D. = standard deviation.
| Compound | IC50 (µM) ± S.D. | |||||
|---|---|---|---|---|---|---|
| BxPC3 | HCT-15 | MCF-7 | A431 | A375 | A549 | |
| [HB(pz)3]Ag (PTA) (1) | 6.6 ± 2.8 | 8.5 ± 1.8 | 6.5 ± 3.1 | 10.3 ± 1.0 | 8.1 ± 1.0 | 5.1 ± 1.2 |
| [HB(pz)3]Ag (DAPTA) (2) | 7.6 ± 2.3 | 7.6 ± 2.0 | 7.4 ± 4.1 | 6.7 ± 1.3 | 9.2 ± 0.1 | 7.5 ± 0.1 |
| [HB(pz)3]Ag (PTA-SO2) (3) | 5.1 ± 1.4 | 7.4 ± 2.2 | 5.1 ± 1.7 | 4.5 ± 1.2 | 5.2 ± 2.1 | 8.3 ± 2.0 |
| [HB(pz)3]Ag (PCN) (4) | 5.6 ± 1.9 | 3.3 ± 1.2 | 5.1 ± 1.4 | 2.9 ± 1.0 | 8.9 ± 2.5 | 4.1 ± 1.0 |
| [HB(pz)3]Ag (PPh3) (5) | 4.4 ± 1.6 | 2.1 ± 0.6 | 2.9 ± 1.0 | 1.5 ± 0.5 | 2.2 ± 0.7 | 2.1 ± 0.6 |
| [Ag (PTA)4]BF4 (6) | 13.2 ± 2.2 | 10.2 ± 3.1 | 11.5 ± 1.8 | 9.3 ± 2.2 | 8.2 ± 4.1 | 10.2 ± 2.5 |
| [Ag (DAPTA)4]BF4 (7) | 7.5 ± 3.2 | 16.2 ± 7.2 | 11.3 ± 2.2 | 11.2 ± 2.1 | 9.1 ± 2.2 | 8.5 ± 3.3 |
| [Ag (PTA-SO2)4]BF4 (8) | 5.3 ± 5.5 | 17.7 ± 4.6 | 12.2 ± 1.6 | 4.1 ± 1.2 | 6.3 ± 3.3 | 13.2 ± 2.5 |
| [Ag (PCN)2]BF4 (9) | 3.1 ± 1.6 | 3.6 ± 1.1 | 4.0 ± 1.0 | 2.9 ± 0.5 | 5.3 ± 1.1 | 5.5 ± 1.6 |
| [Ag (PPh3)4]BF4 (10) | 3.1 ± 0.8 | 3.4 ± 1.0 | 5.1 ± 1.2 | 2.0 ± 0.5 | 3.2 ± 1.1 | 3.0 ± 1.0 |
| PTA | >100 | >100 | >100 | >100 | >100 | >100 |
| DAPTA | 89.5 ± 4.1 | 67.1 ± 3.1 | 85.3 ± 4.0 | >100 | >100 | >100 |
| PCN | >100 | >100 | >100 | >100 | >100 | >100 |
| PPh3 | 62.2 ± 2.2 | 54.1 ± 4.2 | 34.2 ± 3.4 | 47.5 ± 1.1 | 52.3 ± 2.5 | 30.1 ± 2.1 |
| PTA-SO2 | >100 | >100 | 69.5 ± 3.4 | 56.0 ± 3.5 | >100 | >100 |
| Na(HBpz3) | 97.4 ± 2.2 | 77.6 ± 2.0 | >100 | 40.4 ± 1.4 | 66.9 ± 2.3 | >100 |
| Cisplatin | 10.2 ± 1.7 | 15.5 ± 2.5 | 7.6 ± 3.0 | 2.1 ± 0.4 | 4.0 ± 1.0 | 8.4 ± 0.9 |